ReviewNeurosurgery clinics of North America2019
Molecular Pathogenesis of Low-Grade Glioma.
Review in Neurosurgery clinics of North America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- A Coordinated Mitochondrial Genome Expression Program Marks a Differentiated Neural-Lineage and Synaptic Transcriptional State in Lower-Grade Glioma.International journal of molecular sciences · 2026Article
- AMPAR Subunit Gene Expression Marks a Synaptic Transcriptional State in Lower-Grade Glioma.Brain sciences · 2026Article
- Brain Cancer: Molecular Alterations and Emerging Trends in Neuropharmacology.International journal of molecular sciences · 2026Review
- Article
- Article
- Screening of potential key pathogenic and intervention targets of low-grade glioma based on bioinformatics.Translational cancer research · 2024Article
- Revealing the role of SPP1Cell & bioscience · 2024Article
- Enhanced Multimodal Brain Tumor Classification in MR Images using 2D ResNet as backbone with Explicit Tumor Size Information.Journal of Cancer · 2024Article
- Review
- PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas.NPJ genomic medicine · 2023Article
- DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets.Cancers · 2023Review
- Risk factors for early progression of diffuse low-grade glioma in adults.Chinese neurosurgical journal · 2022Article
- Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series.Genes · 2022Article
- CMTM Family Genes Affect Prognosis and Modulate Immunocytes Infiltration in Grade II/III Glioma Patients by Influencing the Tumor Immune Landscape and Activating Associated Immunosuppressing Pathways.Frontiers in cell and developmental biology · 2022Article
- Case report: ISL2 is involved in malignant transformation in a patient with multiple relapsed oligodendroglioma.Frontiers in oncology · 2022Article
- Characterization of the Ferroptosis-Related Genes for Prognosis and Immune Infiltration in Low-Grade Glioma.Frontiers in genetics · 2022Article
- Heterogeneous parameters based onQuantitative imaging in medicine and surgery · 2021Article
- Correction to: Advanced imaging in adult diffusely infiltrating low-grade gliomas.Insights into imaging · 2020Article
- Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients.Disease markers · 2020Article
- OSlgg: An Online Prognostic Biomarker Analysis Tool for Low-Grade Glioma.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Advances in genome sequencing have elucidated the genetics of low-grade glioma. Available evidence indicates a neomorphic mutation in isocitrate dehydrogenase (IDH) initiates gliomagenesis. Mutant IDH produces the oncometabolite 2-hydroxyglutarate, which inhibits enzymes that demethylate genomic DNA and histones. Recent findings by the authors and others suggest the ensuing hypermethylation alters chromatin conformation and the transcription factor landscape in brain progenitor cells, leading to a block in differentiation and tumor initiation. Work in preclinical models has identified selective metabolic and molecular vulnerabilities of low-grade glioma. These new concepts will trigger a wave of innovative clinical trials in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.